A single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti–Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma

Trial Profile

A single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti–Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs BI 505 (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors BioInvent International
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Mar 2015 Status changed from recruiting to discontinued, as reported in a BioInvent International media release.
    • 23 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01838369).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top